Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(0)
•••
Comment by lovetheoilpatchon May 08, 2015 3:47pm
128 Views
Post# 23709893

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Drug-Packed Exosomes v. BTI

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Drug-Packed Exosomes v. BTIDoctor jekyll...of i may speak for the majority here...but i think what your trying to say amd which i concurr with fully is that geva got a 8.4billion dollar deal done...we dont have $hit compared to them.....regardless of what we think we have ...the dont think....they had a massive buyout....who cares where their science ends up.. simply put why are we discussing a company like that anyway?...j.d how can you sit there and even try to make a comparison?...we are nowhere neear the realm that they were....take away the science from both companys and geva is still eons ahead financially. ..because of american fund managers..goldman sachs..j.p morgan....and the likes....coupled with the fact t that we are traded on one of the worst exchanges around...where investment is marred by the fact that peaople constantly get fleeced here...it doesnt help out cause....on the nasdaq we would probably be sitting at or around 7$ with what we have now...we have zero failure and only great things accomplished. ...prob be even higher....plus ..wed get the pump of a lifetime with every great news we get released....i just see hopefullness from many here...
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities